The rationality for using prodrug approach in drug discovery programs for new xenobiotics: Opportunities and challenges

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 36, Issue 2, 2011, Pages 49-59

  Srinivas, Nuggehally R ^a  

^a Vanthys Pharmaceutical Development Pvt Ltd   (India)

Author keywords

Absorption; Biopharmaceutics; Drug delivery; Drug discovery; Pharmacokinetics; Prodrugs

Indexed keywords

ACICLOVIR; AMPICILLIN; AMPRENAVIR; AZATHIOPRINE; CEFTAROLINE; CEFTAROLINE FOSAMIL; CEFTOBIPROLE; CEFTOBIPROLE MEDOCARIL; COLISTIMETHATE; COLISTIN; DEXAMPHETAMINE; DIPYRIDAMOLE; FLURBIPROFEN; FOSAMPRENAVIR; FOSPROPOFOL; KETOROLAC; LANINAMIVIR; LANINAMIVIR OCTANOATE; LENAMPICILLIN; LINEZOLID; LISDEXAMFETAMINE; METFORMIN; OSELTAMIVIR; PIVAMPICILLIN; PRODRUG; PROPOFOL; RITONAVIR; TEDIZOLID; UNINDEXED DRUG; VALACICLOVIR; XENOBIOTIC AGENT;

ANTIBACTERIAL ACTIVITY; ATTENTION DEFICIT DISORDER; BACTERICIDAL ACTIVITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEGRADATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG RESEARCH; DRUG SOLUBILITY; DRUG TRANSFORMATION; GENETIC POLYMORPHISM; GRAM NEGATIVE INFECTION; HAEMOPHILUS INFECTION; HUMAN; INFLUENZA; LIPOPHILICITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORAXELLACEAE INFECTION; MULTIPLE DRUG DOSE; NONHUMAN; REVIEW; SINGLE DRUG DOSE; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; ANIMAL; CLINICAL PHARMACOLOGY; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; METHODOLOGY;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; PHARMACOLOGY, CLINICAL; PRODRUGS; XENOBIOTICS;

EID: 80052542982     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-011-0035-z     Document Type: Review

References (60)

1. Ancrenaz V, Daali Y, Fontana P, Besson M, Samer C, Dayer P, Desmeules J (2010) Impact of genetic polymorphisms and drug- drug interactions on clopidogrel and prasugrel response variability. Curr Drug Metab 11:667-677.
2. Angiolillo DJ, Gibson CM, Cheng S, Ollier C, Nicolas O, Bergougnan L, Perrin L, LaCreta FP, Hurbin F, Dubar M (2011) Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 89:65-74.
3. Bhandari KH, Newa M, Yoon SI, Kim JS, Kim DD, Kim JA, Yoo BK, Woo JS, Lyoo WS, Choi JY, Lim HT, Lee JH, Choi HG, Yong CS (2007) Evaluation of skin permeation and accumulation profiles of ketorolac fatty esters. J Pharm Pharm Sci 10:278-287.
4. Biederman J, Boellner SW, Childress A, Lopez FA, Krishnan S, Zhang Y (2007a) Lisdexamfetamine dimesylate and mixedamphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 62:970-976. (Pubitemid 47562371)
5. Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL (2007b) Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 29:450-463. (Pubitemid 46924786)
6. Brouwers J, Tack J, Augustijns P (2007) Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state. Pharm Res 24:1862-1869. (Pubitemid 47389240)
7. Browning MR, Drexler DM, Olah TV, Morgan DG (2010) Simultaneous bioanalysis of a phosphate prodrug and its parent compound using a multiplexed LC-MS method. Bioanalysis 2:745-753.
8. Cai ZW, Zhang Y, Borzilleri RM, Qian L, Barbosa S, Wei D, Zheng X, Wu L, Fan J, Shi Z, Wautlet BS, Mortillo S, Jeyaseelan R Sr, Kukral DW, Kamath A, Marathe P, D'Arienzo C, Derbin G, Barrish JC, Robl JA, Hunt JT, Lombardo LJ, Fargnoli J, Bhide RS (2008) Discovery of brivanib alaninate ((S)-((R)-1-(4-(4- fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2, 1-f][1, 2, 4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS- 540215). J Med Chem 51:1976-1980. (Pubitemid 351438880)
9. Chang Q, Chow MSS, Zuo Z (2009) Studies on the influence of esterase inhibitor to the pharmacokinetic profiles of oseltamivir and oseltamivir carboxylate in rats using an improved LC/MS/MS method. Biomed Chromatogr 23:852-857.
10. Chen BL, Chen Y, Tu JH, Li YL, Zhang W, Li Q, Fan L, Tan ZR, Hu DL, Wang D, Wang LS, Ouyang DS, Zhou HH (2009) Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms. J Clin Pharmacol 49:574-581.
11. Curcio A, Sasso O, Melisi D, Nieddu M, La Rana G, Russo R, Gavini E, Boatto G, Abignente E, Calignano A, Rimoli MG (2009) Galactosyl prodrug of ketorolac: synthesis, stability, and pharmacological and pharmacokinetic evaluations. J Med Chem 52:3794-3800.
12. D'Arienzo CJ, Ji QC, Discenza L, Cornelius G, Hynes J, Cornelius L, Santella JB, Olah T (2010) DBS sampling can be used to stabilize prodrugs in drug discovery rodent studies without the addition of esterase inhibitors. Bioanalysis 2:1415-1422.
13. Dahan A, Duvdevani R, Shapiro I, Elmann A, Finkelstein E, Hoffman A (2008) The oral absorption of phospholipid prodrugs: in vivo and in vitro mechanistic investigation of trafficking of a lecithin- valproic acid conjugate following oral administration. J Control Release 126:1-9.
14. Daikos GL, Skiada A, Pavleas J, Vafiadi C, Salatas K, Tofas P, Tzanetou K, Markogiannakis A, Thomopoulos G, Vafiadi I, Petrikkos G (2010) Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use. J Chemother 22:175-178.
15. Dang Q, Liu Y, Cashion DK, Kasibhatla SR, Jiang T, Taplin F, Jacintho JD, Li H, Sun Z, Fan Y, Dare J, Tian F, Li W, Gibson T, Lemus R, van Poelje PD, Potter SC, Erion MD (2011) Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1, 6-bisphosphatase. J Med Chem 54:153-165.
16. Del Pozo JL, Patel R (2008) Ceftobiprole medocaril: a new generation beta-lactam. Drugs Today (Barc) 44:801-825.
17. Erbe DV, Klaman LD, Wilson DP, Wan ZK, Kirincich SJ, Will S, Xu X, Kung L, Wang S, Tam S, Lee J, Tobin JF (2009) Prodrug delivery of novel PTP1B inhibitors to enhance insulin signaling. Diabetes Obes Metab 11:579-588.
18. Faraone SV (2008) Lisdexamfetamine dimesylate: the first longacting prodrug stimulant treatment for attention deficit/hyperactivity disorder. Expert Opin Pharmacother 9:1565-1574. (Pubitemid 352005916)
19. Farid NA, Kurihara A, Wrighton SA (2010) Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 50:126-142.
20. Fukuhara A, Imai T, Otagiri M (1996) Stereoselective disposition of flurbiprofen from a mutual prodrug with a histamine H2- antagonist to reduce gastrointestinal lesions in the rat. Chirality 8:494-502. (Pubitemid 27009143)
21. Furfine ES, Baker CT, Hale MR, Reynolds DJ, Salisbury JA, Searle AD, Studenberg SD, Todd D, Tung RD, Spaltenstein A (2004) Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob Agents Chemother 48(3):791-798. (Pubitemid 38280326)
22. Granero GE, Amidon GL (2006) Stability of valacyclovir: implications for its oral bioavailability. Int J Pharm 317:14-18. (Pubitemid 43866338)
23. Guibert J, Kitzis MD, Yamabe S, Acar JF (1985) Single- and multiple-dose pharmacokinetics of lenampicillin (KBT-1585) in healthy human subjects: comparative studies with amoxicillin. Chemioterapia 4:293-298. (Pubitemid 15242833)
24. Gullick DR, Pugh WJ, Ingram MJ, Cox PA, Moss GP (2010) Formulation and characterization of a captopril ethyl ester drugin- adhesive-type patch for percutaneous absorption. Drug Dev Ind Pharm 36:926-932.
25. Hara K, Suyama K, Itoh H, Nagashima S (2008) Influence of ALDH2 genetic polymorphisms on acyclovir pharmacokinetics following oral administration of valacyclovir in Japanese end-stage renal disease patients. Drug Metab Pharmacokinet 23:306-312.
26. Howland RH (2008) Lisdexamfetamine: a prodrug stimulant for ADHD. J Psychosoc Nurs Ment Health Serv 46:19-22.
27. Hsieh PW, Hung CF, Fang JY (2009) Current prodrug design for drug discovery. Curr Pharm Des 15(19):2236-2250.
28. Humphreys WG (2011) Overview of strategies for addressing BRIS in drug discovery: impact on optimization and design. Chem Biol Interact [Epub ahead of print].
29. Huttunen KM, Mannila A, Laine K, Kemppainen E, Leppanen J, Vepsalainen J, Jarvinen T, Rautio J (2009) The first bioreversible prodrug of metformin with improved lipophilicity and enhanced intestinal absorption. J Med Chem 52:4142-4148.
30. Jasinski D, Krishnan S (2009) Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol 23:419-427.
31. Klein T, Abgottspon D, Wittwer M, Rabbani S, Herold J, Jiang X, Kleeb S, Lü thi C, Scharenberg M, Bezençon J, Gubler E, Pang L, Smiesko M, Cutting B, Schwardt O, Ernst B (2010) FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J Med Chem 53:8627-8641.
32. Krishnan S, Montcrief S (2007) Toxicity profile of lisdexamfetamine dimesylate in three independent rat toxicology studies. Basic Clin Pharmacol Toxicol 101:231-240. (Pubitemid 350194801)
33. Lalanne M, Khoury H, Deroussent A, Bosquet N, Benech H, Clayette P, Couvreur P, Vassal G, Paci A, Andrieux K (2009) Metabolism evaluation of biomimetic prodrugs by in vitro models and mass spectrometry. Int J Pharm 379:235-243.
34. Lee J, Bae S, Lee SH, Choi H, Kim YH, Kim SJ, Park GT, Moon SK, Kim DH, Lee S, Ahn SK, Choi NS, Lee KJ (2010) Discovery of a potent tubulin polymerization inhibitor: synthesis and evaluation of water-soluble prodrugs of benzophenone analog. Bioorg Med Chem Lett 20:6327-6330.
35. Leone F, Akl A, Giral M, Dantal J, Blancho G, Soulillou JP, Cantarovich D (2010) Six months anti-viral prophylaxis significantly decreased cytomegalovirus disease compared with no anti-viral prophylaxis following renal transplantation. Transpl Int 23:897-906.
36. Liederer BM, Borchardt RT (2005) Stability of oxymethyl-modified coumarinic acid cyclic prodrugs of diastereomeric opioid peptides in biological media from various animal species including human. J Pharm Sci 94:2198-2206. (Pubitemid 41665281)
37. Lo WY, Balasubramanian A, Helsby NA (2009) Hydrolysis of dinitrobenzamide phosphate prodrugs: the role of alkaline phosphatase. Drug Metabol Drug Interact 24:1-16.
38. Mackman RL, Ray AS, Hui HC, Zhang L, Birkus G, Boojamra CG, Desai MC, Douglas JL, Gao Y, Grant D, Laflamme G, Lin KY, Markevitch DY, Mishra R, McDermott M, Pakdaman R, Petrakovsky OV, Vela JE, Cihlar T (2010) Discovery of GS- 9131: design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148. Bioorg Med Chem 18:3606-3617.
39. Marathe PH, Kamath AV, Zhang Y, D'Arienzo C, Bhide R, Fargnoli J (2009) Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. Cancer Chemother Pharmacol 65:55-66.
40. Mizuma T (2010) Kinetic assessment of luminal degradation of orally effective prodrugs for rational drug development. J Pharm Sci 99:1078-1086.
41. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H (2009) Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 53(8):3430-3436.
42. Prokocimer P, Bien P, Surber J, Mehra P, DeAnda C, Bulitta JB, Corey GR (2011) Phase 2, randomized, double-blind, doseranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 55:583-592.
43. Quon CY, Mai K, Patil G, Stampfli HF (1988) Species differences in the stereoselective hydrolysis of esmolol by blood esterases. Drug Metab Dispos 16:425-428.
44. Rautio J, Leppänen J, Lehtonen M, Laine K, Koskinen M, Pystynen J, Savolainen J, Sairanen M (2010) Design, synthesis and in vitro/in vivo evaluation of orally bioavailable prodrugs of a catechol- O-methyltransferase inhibitor. Bioorg Med Chem Lett 20:2614-2616.
45. Ruane PJ, Luber AD, Wire MB, Lou Y, Shelton MJ, Lancaster CT, Pappa KA (2007) COL10053 Study Team. Plasma amprenavir pharmacokinetics and tolerability following administration of 1, 400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. Antimicrob Agents Chemother 51(2):560-565. (Pubitemid 46185273)
46. Sams AG, Mikkelsen GK, Larsen M, Langgard M, Howells ME, Schrøder TJ, Brennum LT, Torup L, Jørgensen EB, Bundgaard C, Kreilgard M, Bang-Andersen B (2011) Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3, 3-dimethyl-butyrylamino)-3, 5-difluorobenzoylimino]- thiazol-3-ylmethyl} Ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist. J Med Chem [Epub ahead of print].
47. Schaadt R, Sweeney D, Shinabarger D, Zurenko G (2009) In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob Agents Chemother 53(8):3236-3239.
48. Srinivas NR, Hubbard JW, McKay G, Hawes EM, Midha KK (1991) In vitro hydrolysis of RR, SS-threo-methylphenidate by blood esterases-differential and enantioselective interspecies variability. Chirality 3:99-103.
49. Steed ME, Rybak MJ (2010) Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens. Pharmacotherapy 30:375-389.
50. Stella VJ (2010) Prodrugs: Some thoughts and current issues. J Pharm Sci 99:4755-4765.
51. Sun J, Dahan A, Amidon GL (2010) Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach. J Med Chem 53:624-632.
52. Takahashi S, Katoh M, Saitoh T, Nakajima M, Yokoi T (2009) Different inhibitory effects in rat and human carboxylesterases. Drug Metab Dispos 37:956-961.
53. Tani C, Mosca M, Colucci R, Gori G, d'Ascanio A, Ghisu N, Fornai M, Di Paolo A, Blandizzi C, Del Tacca M, Bombardieri S (2009) Genetic polymorphisms of thiopurine S-methyltransferase in a cohort of patients with systemic autoimmune diseases. Clin Exp Rheumatol 27:321-324.
54. Thomas HD, Saravanan K, Wang LZ, Lin MJ, Northen JS, Barlow H, Barton M, Newell DR, Griffin RJ, Golding BT, Curtin NJ (2009) Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity. Mol Cancer Ther 8:1828-1837.
55. Verbist L (1974) Triple crossover study on absorption and excretion of ampicillin, pivampicillin, and amoxycillin. Antimicrob Agents Chemother 6:588-593.
56. Wallace SJ, Li J, Rayner CR, Coulthard K, Nation RL (2008) Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients. Antimicrob Agents Chemother 52:3047-3051.
57. Welliver M, Rugari SM (2009) New drug, fospropofol disodium: a propofol prodrug. AANA J 77:301-308.
58. Yamashita M (2010) Laninamivir and its prodrug, CS-8958: longacting neuraminidase inhibitors for the treatment of influenza. Antivir Chem Chemother 21:71-84.
59. Zhou T, Hider RC, Jenner P, Campbell B, Hobbs CJ, Rose S, Jairaj M, Tayarani-Binazir KA, Syme A (2010) Design, synthesis and biological evaluation of L-dopa amide derivatives as potential prodrugs for the treatment of Parkinson's disease. Eur J Med Chem 45:4035-4042.
60. Zhu HJ, Markowitz JS (2009) Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. Drug Metab Dispos 37:264-267.